Progressive Relaxation for COPD: Effects on Insomnia and Satisfaction

What Was Tested

The trial (not phased) is built around Relaxin (Serelaxin).

In the life model based on the activities of living developed by nursing theorists Roper, Logan, and Tierney, sleep is identified as one of the twelve essential activities.

Sleep is a fundamental need initiated by the circadian rhythm and sleep/wake homeostatic pressure, and it is followed by a period of wakefulness.

It had two arms (groups): Intervention Group (experimental) and Control Group (no intervention).

Implementation of Progressive Muscle Relaxation Training.

The registry classes the interventions as other.

Who Took Part

70 planned participants were the target.

It was open to people of any sex aged from 18 years up to 85 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Being diagnosed with chronic obstructive pulmonary disease (COPD).

The full record lists 1 inclusion and 1 exclusion criteria; among the exclusions: participants must not be under 18 years of age.

How the Study Was Run

Design: randomized, parallel-group and double-blind.

Random assignment meant chance, not the researchers, decided who got Relaxin (Serelaxin) and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Neither the participants nor the staff measuring them knew who was on Relaxin (Serelaxin), so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and investigator.

It started in 2025-02-01 with completion listed for 2025-08-22.

It ran at 1 site in Turkey (Türkiye).

Its stated primary purpose is supportive care.

What Was Measured

The main thing measured (primary outcome): Hospital-Related Insomnia Scale: (time frame: 7 day).

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Relaxin (Serelaxin) in 70 people.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Relaxin (Serelaxin) compound page, all human trials.